Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis

Area of Science:

• Parasitology
• Immunology
• Drug Discovery

Background:

• Toxoplasma gondii infection remains a significant global health and economic burden.
• Improved diagnostics, vaccines, and chemotherapy are crucial for managing toxoplasmosis.
• The ROP8 protein is vital for parasite invasion and parasitophorous vacuole formation.

Purpose of the Study:

• To evaluate the diagnostic, immunoprophylactic, and therapeutic potential of recombinant ROP8 (rROP8).
• To explore rROP8 as a target for novel anti-Toxoplasma drug development.

Main Methods:

• Recombinant ROP8 (rROP8) protein was expressed and purified.
• Diagnostic potential assessed using ELISA on human and mouse sera.
• Immunogenic properties evaluated through in vitro immune cell stimulation and cytokine profiling.
• Drug interactions investigated using DARTS assays and confocal microscopy.

Main Results:

• rROP8 effectively detected specific IgG antibodies in infected mouse and human sera.
• rROP8 activated human monocytes and mouse macrophages, enhancing parasite clearance.
• rROP8 stimulated human dendritic cells, promoting a Th1/Th17 immune response.
• Thiazolidin-4-one derivatives inhibited rROP8 degradation, indicating therapeutic potential.

Conclusions:

• Recombinant ROP8 is a promising candidate for Toxoplasma gondii diagnostics and immunomodulation.
• rROP8 serves as a valuable target for developing novel anti-parasitic drugs.
• Further research into rROP8-based strategies could significantly improve toxoplasmosis management.